导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.46% | 2011/4407 |
| 近一周 | -2.09% | 3699/5016 |
| 近一月 | -2.62% | 940/4972 |
| 近一季 | -6.55% | 1922/4811 |
| 近半年 | -7.47% | 3193/4547 |
| 近一年 | 3.90% | 1642/4077 |
| 近两年 | 31.29% | 2059/2754 |
| 近三年 | 22.23% | 1271/2082 |
| 成立以来 | 101.56% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.51% 716/4961 |
1.53% 3012/5312 |
- - |
- - |
| 2025 | 7.38% 2927/4813 |
-4.37% 3169/3635 |
1.15% 2442/4076 |
7.46% 3449/4524 |
3.30% 701/4813 |
| 2024 | 20.66% 450/3463 |
9.73% 117/2808 |
2.20% 377/3014 |
8.13% 2769/3129 |
-0.51% 1446/3463 |
| 2023 | 8.18% 130/2656 |
16.97% 186/2280 |
1.12% 236/2385 |
-3.25% 882/2515 |
-5.47% 1366/2655 |
| 2022 | -12.45% 285/2207 |
-10.92% 456/1919 |
2.74% 1261/2016 |
-9.72% 301/2113 |
5.96% 406/2208 |
| 2021 | 33.07% 53/1822 |
4.03% 162/1255 |
5.18% 820/1330 |
19.63% 49/1466 |
1.66% 844/1822 |
| 2020 | 16.89% 771/1250 |
-6.31% 478/1028 |
0.05% 1009/1067 |
12.21% 401/1164 |
11.13% 562/1184 |
| 2019 | - - |
- - |
- - |
- - |
-0.97% 894/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 富国央企创新ETF VS. 长安沪深300非周期A(740101) |